ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Malignancy"

  • 2016 American Transplant Congress

    Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.

    D. Dahle,1 T. Grotmol,2 T. Leivestad,3 A. Hartmann,1 G. Mjøen,1 H. Pihlstrøm,1 H. Næss,1 H. Holdaas.1

    1Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway; 2The Cancer Registry of Norway, Oslo, Norway; 3Norwegian Renal Registry, Oslo University Hospital, Oslo, Norway.

    In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…
  • 2016 American Transplant Congress

    Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.

    E. Maloney, E. Bongen, F. Vallania, N. Kotecha, P. Khatri, O. Martinez.

    Stanford School of Medicine, Stanford, CA.

    EBV is linked to a variety of lymphoid and epithelial malignancies. In transplant recipients EBV is associated with the development of B cell lymphomas in…
  • 2016 American Transplant Congress

    Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.

    S. Chadban,1 H. Pilmore,2 G. Russ,3 J. Kanellis,4 S. Campbell,5 P. O'Connell,6 W. Lim,7 M. Lutherborrow,8 N. Kurstjens,8 R. Walker.9

    1Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; 2Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; 3Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; 4Renal Medicine, Monash Medical Centre, Melbourne, Australia; 5University of Queensland, Princess Alexandra Hospital, Queensland, Australia; 6Renal Medicine, Westmead Hospital, Sydney, Australia; 7WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; 8Novartis Pharmaceuticals, Sydney, Australia; 9Renal Medicine, Alfred Hospital, Melbourne, Australia.

    A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
  • 2016 American Transplant Congress

    Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.

    S. Acuna,1,2,3 R. Sutradhar,1,2 J. Kim,1,2,4 N. Baxter.1,2,3

    1Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; 2Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; 3Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; 4Department of Medicine, University Health Network, Toronto, ON, Canada.

    Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…
  • 2015 American Transplant Congress

    Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death

    R. Carroll,1 A. Phillippe,2 R. Catar,2 H. Heidecke,2 D. Dragun.2

    1Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; 2Centre for Cardiovascular Research, Charite Hospital, Berlin, Germany.

    We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…
  • 2015 American Transplant Congress

    Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation

    P. De Simone,1 P. Carrai,1 L. Coletti,1 D. Ghinolfi,1 D. Campani,2 F. Filipponi.1

    1Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; 2Pathology, University of Pisa Medical School Hospital, Pisa, Italy.

    Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…
  • 2015 American Transplant Congress

    Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center

    L. Mesa, E. Manzi, M. Valderrama, J. Posada, J. Schweineberg, C. Duran, G. Echeverri, J. Villegas, O. Serrano, L. Caicedo.

    Transplant Unit, Fundación Valle del Lili, Cali, Colombia.

    Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…
  • 2015 American Transplant Congress

    Allo-Stimulated Interferon-γ Release and Natural Killer Cell Function Defines and Risk Stratifies Cancer Development in Kidney Transplant Recipients Who Have Cancer Post-transplantation

    C. Hope,1,2 A. Fuss,1,2 W. Hanf,1 P. Coates,1,2 P. Heeger,3 R. Carroll.1,2

    1The Centre for Clinical and Experimental Transplantation (CCET), Central Northern Adelaide Renal and Transplantation Services (CNARTS), Adelaide, South Australia, Australia; 2Medicine, The University of Adelaide, Adelaide, South Australia, Australia; 3Icahn School of Medicine, The Recanati-Miller Transplant Institute, New York City, NY.

    Reducing immunosuppression is efficacious in primary prevention of cancer in Kidney Transplant Recipients (KTR) but can precipitate graft rejection. Conventional immunosuppressive drug monitoring fails to…
  • 2015 American Transplant Congress

    Early Detection of HCC Mutations in Indeterminate Lesions Using Liquid Biopsies

    Y. Lin,1 K. Cavaness,2 Z. Zhang,1 S. Lin,3 K. Korenblat,1 G. Klintmalm,2 W. Chapman.1

    1Washington University, St. Louis, MO; 2Baylor University, Dallas, TX; 3Stanford University, Palo Alto, CA.

    Background Recent sequencing efforts have characterized the mutation profile of hepatocellular carcinoma (HCC); however, the relevance to clinical decision-making has been limited by the infrequency…
  • 2015 American Transplant Congress

    Risk Factors Influencing Mammography Screening During Kidney Transplant Evaluation

    J. Stoecker, D. Cote, J. Augustine, N. Sarabu, J. Schulak, E. Sanchez, V. Humphreville, J. Ammori, K. Woodside.

    Transplant Institute, University Hospitals & Case Western Reserve University, Cleveland, OH.

    INTRO:Transplant centers typically require mammography (MMG) for women ≥ 40 as part of the evaluation process. The American Cancer Society recommends annual mammograms for the…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences